- Zacks Small Cap Research•4 days ago
On September 14, Resverlogix Corp. (RVX.TO) submitted its financial filings for its first quarter of fiscal year 2017 ending July 31, 2016 to the Alberta Securities Commission. The company reported no revenues and a net loss of ($6.5) million or ($0.06) per share. This compares to our estimates also of zero revenues and a net loss of ($4.4) million or ($0.04) per share. Total operational expenses for 1Q:17 were $7.1 million, increasing from $3.5 million in the same quarter of the prior year. First quarter research & development expenses rose 183%, while general & administrative fell 27%. Costs related to the BETonMACE clinical trial drove the overall increase.
- PR Newswire•12 days agoResverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
CALGARY, Sept. 14, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements ...
- CNW Group•12 days agoResverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
Resverlogix Corp. (RVX.TO)
Toronto - Toronto Delayed Price. Currency in CAD
|Day's Range||1.65 - 1.93|
|52wk Range||1.10 - 2.52|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-6.39|
|Avg Vol (3m)||32,969|
|Dividend & Yield||N/A (N/A)|